Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

Like this presentation? Why not share!

Like this? Share it with your network

Share

Clinical Trial Phase 3 And 4

on

  • 3,577 views

description of phases 3 and 4 of ct

description of phases 3 and 4 of ct

Statistics

Views

Total Views
3,577
Views on SlideShare
3,577
Embed Views
0

Actions

Likes
1
Downloads
104
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Microsoft PowerPoint

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Clinical Trial Phase 3 And 4 Presentation Transcript

  • 1. CLINICAL TRIAL PHASE 3 AND 4 BY SANCHIT RASTOGI Sunday, November 28, 2010 icri,dehradun
  • 2. PHASE 3
    • Also known as therapeutic confirmatory trials
    • randomized controlled  
    • multicenter trials
    • on large patient groups (300–3,000 or more depending upon the disease/medical condition studied)
    • Safety ,drug interactions are accessed on a larger scale
    • Additional pharmacokinetic data may be obtained.
    • Phase III trials are the most expensive
    • time-consuming
    Sunday, November 28, 2010 icri,dehradun
  • 3. PHASE 3 (CONTINUES)
    • difficult trials to design
    • especially in therapies for chronic medical conditions
    • continue while the regulatory submission is pending at the appropriate regulatory agency.
    Sunday, November 28, 2010 icri,dehradun
  • 4. PHASE 3 CONSIST OF TWO PARTS
    • PHASE 3A
    • Trials carried out on a large number-or in a special category – Regulatory requirement for NDA
    • PHASE 3B
    • Extended trials of IIIa after applying for approval but before launch.
    • Phase 3b studies are known as " label expansion " (to show the drug works for additional types of patients/diseases beyond the original use for which the drug was approved for marketing), to obtain additional safety data, or to support marketing claims for the drug.
    Sunday, November 28, 2010 icri,dehradun
  • 5. New Drug Application (NDA)
    • NDA filing process is applying for marketing approval to regulatory body.
    • Aplication contains often in hundreds of volumes, full reports of all preclinical and clinical data.
    • Review and decision of approval may take 3 years or longer.
    • Controlled marketing allowed for life threatening diseases
    Sunday, November 28, 2010 icri,dehradun
  • 6. Sunday, November 28, 2010 icri,dehradun
  • 7. POST MARKETING SURVEILLANCE
    • Used to describe the research and studies associated with product safety evaluation after the drug has been approved for marketing.
    • Pms=Pharmacovigilance+Pharmacoeconomics+Pharmacoepidemiology.
    • No fix duration
    Sunday, November 28, 2010 icri,dehradun
  • 8. SOME DATES IN THE HISTORY OF PHARMACOVIGILANCE
    • 1848
    • The Lancet starts collecting notifications of side effects after a death caused by anaesthesia
    • 1906
    • US Federal Food and Drug Act requires that pharmaceuticals be “pure” and “free of any contamination”
    • 1937
    • USA: 107 lethal cases after diethylenglycol was mistakenly used to solubilize sulphanilamides
    • 1952
    • France: 100 lethal cases after diethyl tin diodide was mistakenly used in a skin preparation
    Sunday, November 28, 2010 icri,dehradun
  • 9. CONTI……..
    • 1959-61
    • Reports of foetal abnormalities in relation with the use of a new sleep-inducing drug thalidomide (biggest number in Germany)
    • 1962
    • USA revised law requiring to prove safety and efficacy before issuing marketing authorisation
    • 1964
    • UK starts “yellow cards” system
    • 1967
    • WHO’s International Drug Monitoring Programme
    • 1976
    • Drugging of the Americas: inadequacy of safety information
    Sunday, November 28, 2010 icri,dehradun
  • 10. OBJECTIVES OF PMS
        • Conform the efficacy and safety profile in large populations during practice
        • Detect the unknown adverse drug reaction/s
        • Evaluation of over-dosage and treatments
        • Identifications of new indications
        • Evaluation of new formulations, dosages, durations of treatment
        • Evaluation in different age groups / types of patients
    Sunday, November 28, 2010 icri,dehradun
  • 11. PMS METHODOLOGIES
    • Spontaneous reporting system
    • Case reports
    • Cross sectional studies
    • Cohort studies
    Sunday, November 28, 2010 icri,dehradun
  • 12. SPONTANEOUS REPORTING SYSTEM
    • Health care personal suspects that a particular medication is associated with an adverse event observed during the course of caring for a patient, reports the ADE to a formal reporting system.
    • Various reporting systems are:
    • WHO INTERNATIONAL SYSTEM
    • USFDA –MEDWATCH
    • UK –YELLOW CARD SYSTEM
    • NATIONAL PHARMACOVIGILANCE SYSTEM
    Sunday, November 28, 2010 icri,dehradun
  • 13. WHO INTERNATIONAL SYSTEM
    • Established in 1968
    • Headquaters in geneva
    • Who collaborating centre for international drug monitoring-uppsala monitoring centrein sweden
    • Individual case reports of suspected adr are collected and stored in a common database.
    Sunday, November 28, 2010 icri,dehradun
  • 14. Sunday, November 28, 2010 icri,dehradun
  • 15. USFDA –MEDWATCH
    • Allows health care professionals and consumers to report serious adr that they suspect are associated with the drugs and medical devices they prescribe,dispense or use.
    • Reporting can be done on line, by phone, or by submitting the medwatch 3500 form by mail or fax
    Sunday, November 28, 2010 icri,dehradun
  • 16. UK –YELLOW CARD SYSTEM
    • Came into existence in 1964
    • States that “every member of the medical and dental profession in the uk..” to report ..”promptly the details of any untoward condition in a patient which might be the result of drug treatment.
    • Example:halothane in jaundice
    Sunday, November 28, 2010 icri,dehradun
  • 17. Sunday, November 28, 2010 icri,dehradun
  • 18. NATIONAL PHARMACOVIGILANCE SYSTEM INDIA
    • launched by CDSCO in november,2004
    • Aim-to develop the culture of ADR notifications by heatlh care workers country is divided into zone and regions
    • CDSCO , new delhi at the top followed by SETH GS MEDICAL COLLEGE,MUMBAI AND AIIMS IN NEW DELHI
    • Then there are 5 regional centers i.e KOLKATA.MUMBAI,NAGPUR,DELHI,PONDICHERRY
    • 28 peripheral systems spread across the country
    Sunday, November 28, 2010 icri,dehradun
  • 19. COHORT STUDIES
    • Groups of individuals are identified
    • Followed over time to time to determine the incidence of some predetermined outcome
    • Generally is of two types:
    • Prospective study
    • Retrospective study
    Sunday, November 28, 2010 icri,dehradun
  • 20. CASE CONTROL STUDY
    • Allow health care workers to share their individual experiences in published medical literature.
    • Play important role in communicating previously unidentified uses and dangers of drug.
    Sunday, November 28, 2010 icri,dehradun
  • 21. CROSS SECTIONAL STUDIES
    • It is an observational study in which drug exposure and diseased status or symptoms are determined at a single point in time
    Sunday, November 28, 2010 icri,dehradun
  • 22. COMPUTERS IN PMS
    • Arisg
    • Dsnavigator
    • Oracle
    • Argus assurance
    • Expert direct
    • sas
    Sunday, November 28, 2010 icri,dehradun
  • 23. Sunday, November 28, 2010 icri,dehradun
  • 24. Sunday, November 28, 2010 icri,dehradun “ There are 3 actions of a drug: the one we want , the one you don’t want , and the one you don’t know about”
  • 25. FUTHER READING
    • Edwards IR, Aronson Jk , adverse drug reactions: definitions, diagnosis, and management. Lancet 2000:356:1255-9
    • Goyal R.K, basics of hospital and clinical pharmacy,1 st edition, B.S Shah publication, Ahmadabad, pg 261 -277 
    • Tripathi KD,”essentials of medical pharmacology”,jaypee brothers medical publishers,6 th edition,pg no.78-86
    Sunday, November 28, 2010 icri,dehradun
  • 26. Sunday, November 28, 2010 icri,dehradun QUESTIONS? COMMENTS?
  • 27. Sunday, November 28, 2010 icri,dehradun THANK YOU